Udai Kammula
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Udai Kammula sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Udai Kammula: 3 sponsored US clinical trials, 3 recruiting.
Udai Kammula sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, Uveal, with 1 trials.
Upper-quartile sponsor footprint
Udai Kammula sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
NCT03801083
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
NCT03467516
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
What is open in the Udai Kammula pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Melanoma, Uveal (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Udai Kammula: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Udai Kammula sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Udai Kammula page
3 registered trials is a research-attention snapshot, not an endorsement of Udai Kammula or any single study.
- 3 of Udai Kammula's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma, Uveal is the condition Udai Kammula studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma, Uveal trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Udai Kammula pipeline card: 3 registered trials from official public datasets.Report a data error.